Twitter 25 min ago
Botanix Pharmaceuticals Ltd@BotanixPharma
Finish line | Soon, we’re expecting a mid-cycle review meeting with the FDA for our lead product, Sofpironium Bromide - a significant de-risking step on our journey to FDA approval which is on track for Q3 this year. Watch this video to learn more https://bit.ly/BOT_MarketHerald_MidCycle$BOT
Ann: Confirmation Sofpironium Bromide NDA Formally Under Review, page-55
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.015(4.17%) |
Mkt cap ! $624.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 34.0¢ | $1.179M | 3.382M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 101976 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 151653 | 1 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |